Key result
MMP targeting offers promising yet translationally challenging cardioprotection by modulating extracellular matrix remodeling.
Why the study?
Matrix metalloproteinases are promising therapeutic targets in cardiovascular diseases, but clinical translation of MMP-targeting therapies remains challenging due to off-target effects and complex regulatory mechanisms.
This narrative review synthesizes the molecular mechanisms and pathophysiological roles of matrix metalloproteinases in atherosclerosis, myocardial infarction, heart failure, and aortic stenosis, highlighting the potential and translational challenges of selective MMP-targeted therapies.
Answers are grounded in this paper and cite their sources.
Translational challenges preclude MMP inhibitor use in cardiovascular practice; leaves open selective targeting for future trials.
Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases that play a crucial role in extracellular matrix (ECM) remodeling and are implicated in the pathogenesis of various cardiovascular diseases (CVDs). Their dysregulation has been linked to atherosclerosis, myocardial infarction (MI), heart failure (HF), and aortic stenosis, contributing to vascular inflammation, plaque destabilization, and adverse cardiac remodeling. Recent research highlights MMPs' involvement beyond ECM degradation, influencing lipoprotein metabolism, inflammatory signaling, and intracellular processes critical for cardiovascular homeostasis. Despite their pathological role, MMPs remain promising therapeutic targets, with pharmacological inhibitors, gene therapy, and tissue inhibitors of metalloproteinases (TIMPs) emerging as potential interventions. However, the clinical translation of MMP-targeting therapies remains challenging due to off-target effects and complex regulatory mechanisms. This review provides an updated synthesis of the molecular mechanisms, disease-specific roles, and therapeutic implications of MMPs in cardiovascular pathology, aiming to bridge the gap between fundamental research and clinical applications.
No takes yet. Share an insight, caveat, or question.
Tănase et al. (2025) conducted a review in Cardiovascular diseases (atherosclerosis, myocardial infarction, heart failure, aortic stenosis). MMP-targeting therapies (pharmacological inhibitors, TIMPs, gene therapy) was evaluated. Matrix metalloproteinases drive extracellular matrix remodeling and pathology across cardiovascular diseases, representing promising yet translationally challenging therapeutic targets.
Synapse has enriched 10 related papers. Consider them for comparative context: